US 12,492,255 B2
Anti-TREM2 antibodies and methods of use
Catherine Hoofd, Gosselies (BE); Thibaut Janss, Gosselies (BE); Romain Pirson, Gosselies (BE); Virginie Rabolli, Gosselies (BE); Yvonne McGrath, Gosselies (BE); Reece Marillier, Gosselies (BE); Quentin Dubray, Gosselies (BE); Clotilde Hoyos, Gosselies (BE); Julie Chesné, Gosselies (BE); Chiara Martinoli, Milan (IT); Stefan Loverix, Ternat (BE); and Laura Saerens, Gosselies (BE)
Assigned to iTeos Belgium SA, Gosselies (BE)
Filed by iTeos Belgium SA, Gosselies (BE)
Filed on May 23, 2025, as Appl. No. 19/217,020.
Application 19/217,020 is a continuation of application No. 18/821,530, filed on Aug. 30, 2024, abandoned.
Claims priority of provisional application 63/640,439, filed on Apr. 30, 2024.
Claims priority of provisional application 63/580,184, filed on Sep. 1, 2023.
Prior Publication US 2025/0282868 A1, Sep. 11, 2025
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); A61P 37/04 (2006.01)
CPC C07K 16/2803 (2013.01) [A61P 35/00 (2018.01); A61P 37/04 (2018.01); A61K 2039/505 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01)] 25 Claims
 
1. An antibody that specifically binds to TREM2, comprising a VH comprising CDRH1, CDRH2, and CDRH3, and a VL comprising CDRL1, CDRL2, and CDRL3, wherein the CDRH1, CDRH2, and CDRH3 comprise the CDRH1, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 109; and the CDRL1, CDRL2, and CDRL3 comprise the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 121; and wherein the amino acid sequences of the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 of the antibody are determined according to Kabat, Chothia, MacCallum, or IMGT numbering.